lunes, 25 de mayo de 2026

Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study Treatment was center of $1 billion buyout By Jason MastMay 25, 2026 General Assignment Reporter

https://www.statnews.com/2026/05/25/eli-lilly-verv-102-gene-editing-cholesterol-phase-1-trial-data/

No hay comentarios:

Publicar un comentario